RAINBOWRainbow Childrens Medicare Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children's Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, such as routine and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility support, and a range of gynecology treatments, as well as operates private pediatric DNB (Diplomate of National Board) training program offering postgraduate and fellowship opportunities to train future healthcare professionals. Rainbow Children's Medicare Limited was incorporated in 1998 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on RAINBOW — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 24.3% YoY
- • Profit growth: 39.1% YoY
- • ROE: 17.9%
- • MACD: bullish
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 24.3% YoY
- • Profit growth: 39.1% YoY
- • ROE: 17.9%
- • MACD: bullish
Bear case
- • Dividend yield: 0.24%
- • Price vs EMA21: below
- • Price vs SMA50: below
- • 1-month return: -0.6%
Key risks
- • Dividend yield: 0.24%
- • Price vs EMA21: below
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹37.07). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.